Taken together, our findings advocate for the therapeutic potential of Lei-Dab7 or other KCNN2 blockers for FASD and possibly other neurodevelopmental diseases that similarly involve KCNN2 upregulation, such as Angelman syndrome.21 The gene discussed is KCNN2; the disease is Angelman syndrome.